Exploring the transformability of polymer-lipid hybrid nanoparticles and nanomaterial-biology interplay to facilitate tumor penetration, cellular uptake and intracellular targeting of anticancer drugs

Ahmed, Taksim; Liu, Fuh-Ching Franky; Abbasi, Azhar Z.; Soeandy, Chesarahmia Dojo; Zhang, Rui Xue; Prashad, Preethy; Cummins, Carolyn L.; Rauth, Andrew M.; Henderson, Jeffrey T.

doi:10.1080/17425247.2021.1902984

Cited by 14 publications

(13 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…53,54,69,88 To further improve intratumoral distribution and cell uptake, a size−shape transformable PLN was developed. 33 By screening a series of lipids for their physicochemical interactions with designed polymers, myristic acid was selected to prepare PLN that gradually changed size and shape (from larger to smaller, and spherical to spiky) over time under physiological conditions (pH 7.4). The transformability of PLN enhanced tumor penetration, cellular uptake, and fatty acid mediated intracellular trafficking of DOX, as demonstrated in an orthotopic breast tumor mouse model.…”

Section: Synergistic Drug Combination Nanomedicine For Enhancing Chem...mentioning

confidence: 99%

“…The transformability of PLN enhanced tumor penetration, cellular uptake, and fatty acid mediated intracellular trafficking of DOX, as demonstrated in an orthotopic breast tumor mouse model. 33 Overall, the challenges and limitations of drug combination therapy are extensively reviewed in recent review articles. 15,89 Nontargeted combination nanomedicines rely on the EPR effect for passive targeting and tumor accumulation.…”

Section: Synergistic Drug Combination Nanomedicine For Enhancing Chem...mentioning

confidence: 99%

“…To achieve this aim, a thorough investigation is required to understand the interactions between the building blocks of NPs (e.g., polymers, lipids, surfactants, and other excipients) and the drugs/biologics being delivered, as well as the fate of the drug in physiological conditions and their interplay with biology. 33…”

Section: Synergistic Drug Combination Nanomedicine For Enhancing Chem...mentioning

confidence: 99%

See 2 more Smart Citations

Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Ahmed

Liu

et al. 2022

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Globally, a rising burden of complex diseases takes a heavy toll on human lives and poses substantial clinical and economic challenges. This review covers nanomedicine and nanotechnology-enabled advanced drug delivery systems (DDS) designed to address various unmet medical needs. Key nanomedicine and DDSs, currently employed in the clinic to tackle some of these diseases, are discussed focusing on their versatility in diagnostics, anticancer therapy, and diabetes management. Firsthand experiences from our own laboratory and the work of others are presented to provide insights into strategies to design and optimize nanomedicine-and nanotechnology-enabled DDS for enhancing therapeutic outcomes. Computational analysis is also briefly reviewed as a technology for rational design of controlled release DDS. Further explorations of DDS have illuminated the interplay of physiological barriers and their impact on DDS. It is demonstrated how such delivery systems can overcome these barriers for enhanced therapeutic efficacy and how new perspectives of next-generation DDS can be applied clinically.

show abstract

Section: Synergistic Drug Combination Nanomedicine For Enhancing Chem...mentioning

confidence: 99%

Section: Synergistic Drug Combination Nanomedicine For Enhancing Chem...mentioning

confidence: 99%

Section: Synergistic Drug Combination Nanomedicine For Enhancing Chem...mentioning

confidence: 99%

See 1 more Smart Citation

Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Ahmed

Liu

et al. 2022

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…[9][10][11] Various nanocarriers/coatings based on liposomes, polymers, carbon nanomaterials, and inorganic particles have been constructed for loading anticancer drugs. [12][13][14][15] However, these nanocarriers/coatings dramatically increase the particle size and light scattering, which in turn weakens the anticancer effect. Moreover, to identify the location and the tumor size to determine the optimized time conditions for appropriate nanomedicine accumulation within the tumor, various imaging reagents such as Gd 3+ , Mn 2+ , Fe 3 O 4 , and indocyanine green (ICG) have been loaded additionally, enabling magnetic resonance imaging (MRI) or fluorescence imaging.…”

Section: Introductionmentioning

confidence: 99%

Biomimetic smart nanoplatform for dual imaging-guided synergistic cancer therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In fact, the use of nanocarrier systems as an alternative platform to the conventional drug solubilization approaches which use a high concentration of toxic surfactants and/or co-solvents, can lead to the safer and more efficient clinical use of anticancer agents. Nanoparticles can augment drug levels at the site of action via passive and/or active targeting processes and reduce non-specific drug distribution to healthy tissues minimizing drug adverse effects (5). Colchicine, a major alkaloid isolated from the seeds and bulbs of Colchicum autumnale and Gloriosa superba, has exhibited a wide range of therapeutic effects since its discovery by the French chemists P. S. Pelletier and J.…”

Section: Introductionmentioning

confidence: 99%

Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor

et al. 2021

View full text Add to dashboard Cite

Purpose: The ultimate goal of this study is to develop a novel delivery system for a new potent cytotoxic compound, CCI-001, with anti-b tubulin activity, so that the drug can be effectively administered and at the same time its harmful side effects can be reduced. Methods: In the current study, CCI-001 was loaded into serum albumin (SA), using a modified desolvation method, generating CCI-001-SA nanoparticles. Both bovine and human SA were used for the encapsulation of this drug candidate. Optimum conditions for drug loading were achieved when already formed and crosslinked albumin nanoparticles were incubated overnight at 37°C with CCI-001 solutions. The CCI-001-loaded albumin nanoparticles were assessed for average particle diameter and polydispersity, zeta potential, drug loading, in vitro release, morphology and cell toxicity against SW620 and HCT116 colorectal cancer cells. Results: The spherical nanoparticles obtained were negatively charged (~ -30 mV) and had an average diameter of ~ 130 nm, with a narrow size distribution. The in vitro release of CCI-001 from the albumin nanoparticles showed a sustained release pattern over 24 hours without any initial burst release, compared to the fast release of the free drug under experimental conditions. No difference between the SA from the two species in terms of CCI-001 loading was observed. However, a significant difference was observed between the release profiles of CCI-001 from drug-loaded HSA and drug-loaded BSA nanoparticles with HSA nanoparticles showing slower drug release (mean release time, MRT, values of 5.14 ± 0.33 h and 6.88 ± 0.15 h for BSA-NPs and HSA-NPs, respectively, P < 0.01). Cellular toxicity studies showed higher cytotoxicity for CCI-001-SA compared to the free drug (IC50s of 0.62 ± 0.31 nM vs 2.06 ± 0.29 nM in SW620 cells and 0.9 ± 0.1 nM vs 4.2 ± 0.2 nM in HCT116 cells, for CCI-001-HSA NPs and free drug, respectively). Therefore, despite the low drug content level in the HSA nanoparticles of CCI-001, the formulation provides relevant concentrations for further in vivo studies in animal models due to high drug potency. Conclusions: The data support the potential use of albumin as a nanocarrier for CCI-001 in biological systems.

show abstract

Exploring the transformability of polymer-lipid hybrid nanoparticles and nanomaterial-biology interplay to facilitate tumor penetration, cellular uptake and intracellular targeting of anticancer drugs

Cited by 14 publications

References 61 publications

Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs

Biomimetic smart nanoplatform for dual imaging-guided synergistic cancer therapy

Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor

Contact Info

Product

Resources

About